Prediction of regulatory targets of alternative isoforms of the epidermal growth factor receptor in a glioblastoma cell line.
Bayesian Gene Selection Criterion
Bayesian Information Criterion
EGFR
RNAi
Splice variants
Journal
BMC bioinformatics
ISSN: 1471-2105
Titre abrégé: BMC Bioinformatics
Pays: England
ID NLM: 100965194
Informations de publication
Date de publication:
22 Aug 2019
22 Aug 2019
Historique:
received:
06
02
2019
accepted:
11
06
2019
entrez:
24
8
2019
pubmed:
24
8
2019
medline:
15
10
2019
Statut:
epublish
Résumé
The epidermal growth factor receptor (EGFR) is a major regulator of proliferation in tumor cells. Elevated expression levels of EGFR are associated with prognosis and clinical outcomes of patients in a variety of tumor types. There are at least four splice variants of the mRNA encoding four protein isoforms of EGFR in humans, named I through IV. EGFR isoform I is the full-length protein, whereas isoforms II-IV are shorter protein isoforms. Nevertheless, all EGFR isoforms bind the epidermal growth factor (EGF). Although EGFR is an essential target of long-established and successful tumor therapeutics, the exact function and biomarker potential of alternative EGFR isoforms II-IV are unclear, motivating more in-depth analyses. Hence, we analyzed transcriptome data from glioblastoma cell line SF767 to predict target genes regulated by EGFR isoforms II-IV, but not by EGFR isoform I nor other receptors such as HER2, HER3, or HER4. We analyzed the differential expression of potential target genes in a glioblastoma cell line in two nested RNAi experimental conditions and one negative control, contrasting expression with EGF stimulation against expression without EGF stimulation. In one RNAi experiment, we selectively knocked down EGFR splice variant I, while in the other we knocked down all four EGFR splice variants, so the associated effects of EGFR II-IV knock-down can only be inferred indirectly. For this type of nested experimental design, we developed a two-step bioinformatics approach based on the Bayesian Information Criterion for predicting putative target genes of EGFR isoforms II-IV. Finally, we experimentally validated a set of six putative target genes, and we found that qPCR validations confirmed the predictions in all cases. By performing RNAi experiments for three poorly investigated EGFR isoforms, we were able to successfully predict 1140 putative target genes specifically regulated by EGFR isoforms II-IV using the developed Bayesian Gene Selection Criterion (BGSC) approach. This approach is easily utilizable for the analysis of data of other nested experimental designs, and we provide an implementation in R that is easily adaptable to similar data or experimental designs together with all raw datasets used in this study in the BGSC repository, https://github.com/GrosseLab/BGSC .
Sections du résumé
BACKGROUND
BACKGROUND
The epidermal growth factor receptor (EGFR) is a major regulator of proliferation in tumor cells. Elevated expression levels of EGFR are associated with prognosis and clinical outcomes of patients in a variety of tumor types. There are at least four splice variants of the mRNA encoding four protein isoforms of EGFR in humans, named I through IV. EGFR isoform I is the full-length protein, whereas isoforms II-IV are shorter protein isoforms. Nevertheless, all EGFR isoforms bind the epidermal growth factor (EGF). Although EGFR is an essential target of long-established and successful tumor therapeutics, the exact function and biomarker potential of alternative EGFR isoforms II-IV are unclear, motivating more in-depth analyses. Hence, we analyzed transcriptome data from glioblastoma cell line SF767 to predict target genes regulated by EGFR isoforms II-IV, but not by EGFR isoform I nor other receptors such as HER2, HER3, or HER4.
RESULTS
RESULTS
We analyzed the differential expression of potential target genes in a glioblastoma cell line in two nested RNAi experimental conditions and one negative control, contrasting expression with EGF stimulation against expression without EGF stimulation. In one RNAi experiment, we selectively knocked down EGFR splice variant I, while in the other we knocked down all four EGFR splice variants, so the associated effects of EGFR II-IV knock-down can only be inferred indirectly. For this type of nested experimental design, we developed a two-step bioinformatics approach based on the Bayesian Information Criterion for predicting putative target genes of EGFR isoforms II-IV. Finally, we experimentally validated a set of six putative target genes, and we found that qPCR validations confirmed the predictions in all cases.
CONCLUSIONS
CONCLUSIONS
By performing RNAi experiments for three poorly investigated EGFR isoforms, we were able to successfully predict 1140 putative target genes specifically regulated by EGFR isoforms II-IV using the developed Bayesian Gene Selection Criterion (BGSC) approach. This approach is easily utilizable for the analysis of data of other nested experimental designs, and we provide an implementation in R that is easily adaptable to similar data or experimental designs together with all raw datasets used in this study in the BGSC repository, https://github.com/GrosseLab/BGSC .
Identifiants
pubmed: 31438847
doi: 10.1186/s12859-019-2944-9
pii: 10.1186/s12859-019-2944-9
pmc: PMC6704634
doi:
Substances chimiques
Protein Isoforms
0
RNA, Small Interfering
0
ErbB Receptors
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
434Subventions
Organisme : Deutsche Forschungsgemeinschaft (DE)
ID : project number 197267875 - grant number GR 3526/2
Organisme : Bundesministerium für Bildung und Forschung (DE)
ID : FKZ: 16/18, 19/13, 21/25
Organisme : Bundesministerium für Bildung und Forschung
ID : FKZ: 16/18, 19/13, 21/25
Organisme : Bundesministerium für Bildung und Forschung (DE)
ID : FKZ 24/19
Organisme : Deutsche Forschungsgemeinschaft (DE)
ID : project number 251444481 - grant number GR 3526/6
Références
J Biol Chem. 2001 Jun 8;276(23):19937-44
pubmed: 11259426
Eur J Cancer. 2001 Sep;37 Suppl 4:S3-8
pubmed: 11597398
Ann N Y Acad Sci. 2003 May;995:39-47
pubmed: 12814937
Lancet Oncol. 2003 Jul;4(7):397-406
pubmed: 12850190
J Hum Genet. 2004;49(3):134-40
pubmed: 14986171
Acta Neuropathol. 2005 Jan;109(1):93-108
pubmed: 15685439
Nat Rev Mol Cell Biol. 2006 Jul;7(7):505-16
pubmed: 16829981
Am J Pathol. 2007 May;170(5):1445-53
pubmed: 17456751
Nat Rev Cancer. 2007 Jun;7(6):429-40
pubmed: 17522712
Acta Oncol. 2007;46(7):951-60
pubmed: 17917826
BMC Bioinformatics. 2008 Jul 18;9:313
pubmed: 18638396
Sci Signal. 2009 Jan 27;2(55):ra4
pubmed: 19176518
Neuro Oncol. 2010 May;12(5):434-43
pubmed: 20406894
Braz J Med Biol Res. 2011 Feb;44(2):112-22
pubmed: 21180879
PLoS One. 2011;6(7):e22423
pubmed: 21811608
Oncogene. 2012 Apr 26;31(17):2237-46
pubmed: 21909135
PLoS One. 2012;7(1):e29921
pubmed: 22253824
EMBO Rep. 2012 Oct;13(10):900-8
pubmed: 22964758
Cancer Biol Ther. 2012 Dec;13(14):1512-21
pubmed: 22990203
Ocul Surf. 2012 Oct;10(4):212-6
pubmed: 23084141
PLoS One. 2012;7(11):e49466
pubmed: 23166678
Biochemistry. 2013 Jul 2;52(26):4531-40
pubmed: 23731208
Oncogenesis. 2013 Sep 30;2:e74
pubmed: 24080956
Nat Protoc. 2013 Nov;8(11):2281-2308
pubmed: 24157548
PLoS One. 2013 Nov 08;8(11):e79895
pubmed: 24260314
Strahlenther Onkol. 2015 Feb;191(2):180-91
pubmed: 25159136
Am J Hum Genet. 2014 Nov 6;95(5):622-32
pubmed: 25439729
Chem Sci. 2014 Dec 1;6(1):237-245
pubmed: 25580214
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
PLoS One. 2015 Feb 27;10(2):e0116610
pubmed: 25723471
Nature. 2015 Dec 3;528(7580):84-7
pubmed: 26570998
Int J Mol Sci. 2016 Apr 19;17(4):
pubmed: 27104520
J Bioenerg Biomembr. 2018 Feb;50(1):33-52
pubmed: 29209894
Oncogene. 2018 Mar;37(10):1386-1398
pubmed: 29321665
PLoS One. 2018 Jul 5;13(7):e0200014
pubmed: 29975751
Onco Targets Ther. 2019 Feb 12;12:1171-1180
pubmed: 30863084